Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0043167 (pertussis)
 19,595 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Five different adjuvants were examined for potentiation of humoral and cell-mediated immune (CMI) responses in cattle to a Brucella abortus soluble antigen (BASA). Two separate experiments were performed involving a total of 64 steers, divided among six groups (Experiment 1) and 9 groups (Experiment 2). The adjuvants used were: muramyl dipeptide, Freund's incomplete adjuvant, dimethyl-dioctadecyl ammonium bromide (DDA), Bordetella pertussis and Propionibacterium acnes. In each experiment, three groups received BASA (2 mg protein) subcutaneously with adjuvant, one group received a reduced dose of B. abortus Strain 19 (S19), one group served as unvaccinated controls, and another group received BASA alone. Primary responses were studied following a single immunization in comparison to the single inoculation with S19. For each experiment serum antibody responses and CMI responses were sequentially determined over a period of 56 days. Antibody responses to B. abortus were measured using the brucellosis card, rivanol precipitation-plate agglutination, complement fixation, and fluorometric immunoassay tests, and as well as with an enzyme-linked immunosorbent assay. The CMI response was measured using antigen-specific lymphoproliferation (LP) and skin testing for delayed-type hypersensitivity (DTH) to BASA (Experiment 2). Specific aspects of induced CMI responses investigated were macrophage activation (IL-1 production), helper T cell activation (IL-2 production), and release of soluble suppressor factor(s). In general, mean antibody responses were significantly higher (P less than 0.05) in immunized steers than in control steers and those receiving BASA alone. The LP responses to heat-killed B. abortus were generally higher in immunized groups than in the controls. The LP and DTH responses were greatest in the groups receiving S19 and BASA + DDA. Increased induction of IL-1 was largest in the group receiving BASA + DDA whereas IL-2 release was greatest in S19 vaccinated steers. Suppressor T cell responses were most obvious in the groups receiving S19, BASA + B. pertussis, and P. acnes. These studies demonstrated that DDA potentiates CMI responses to a soluble B. abortus antigen and may be useful as an adjuvant for future vaccines, particularly subunit vaccines.
 ...
PMID:The effects of adjuvants on immune responses in cattle injected with a Brucella abortus soluble antigen. 183 13

In 2001 there were 104,187 notifications of communicable diseases in Australia reported to the National Notifiable Diseases Surveillance System (NNDSS). The number of notifications in 2001 was an increase of 16 per cent of those reported in 2000 (89,740) and the largest annual total since the NNDSS commenced in 1991. In 2001, nine new diseases were added to the list of diseases reported to NNDSS and four diseases were removed. The new diseases were cryptosporidiosis, laboratory-confirmed influenza, invasive pneumococcal disease, Japanese encephalitis, Kunjin virus infection, Murray Valley encephalitis virus infection, anthrax, Australian bat lyssavirus, and other lyssaviruses (not elsewhere classified). Bloodborne virus infections remained the most frequently notified disease (29,057 reports, 27.9% of total), followed by sexually transmitted infections (27,647, 26.5%), gastrointestinal diseases (26,086, 25%), vaccine preventable diseases (13,030 (12.5%), vectorborne diseases (5,294, 5.1%), other bacterial infections (1,978, 1.9%), zoonotic infections (1,091, 1%) and four cases of quarantinable diseases. In 2001 there were increases in the number of notifications of incident hepatitis C, chlamydial infections, pertussis, Barmah Forest virus infection and ornithosis. There were decreases in the number of notifications of hepatitis A, Haemophilus influenzae type b infections, measles, rubella, Ross River virus infections and brucellosis. This report also summarises data on communicable diseases from other surveillance systems including the Laboratory Virology and Serology Reporting Scheme and sentinel general practitioner schemes. In addition, this report comments on other important developments in communicable disease control in Australia in 2001.
 ...
PMID:Australia's notifiable diseases status, 2001: annual report of the National Notifiable Diseases Surveillance System. 1272 5

Polymyxin is an effective antibiotic for the treatment of severe infections produced by Ps. aeruginosa, H. pertussis, H. influenzae, E. coli, and A. aerogenes. Its toxicity to date precludes its general use in infections susceptible to its therapeutic effects. Chloromycetin has been demonstrated to be an effective antibiotic agent for the treatment of rickettsial diseases and typhoid fever. It will undoubtedly prove effective in the treatment of other infections produced by certain Gram-negative micro-organisms and viral agents. Aureomycin has been shown to be an active antibiotic agent against rickettsial diseases, primary atypical pneumonia, acute brucellosis, pneumococcal, streptococcal, and staphylococcal infections, urinary tract infections produced by E. coli, A. aerogenes and Strept. fecalis, certain types of infections of the eye, and in subacute bacterial endocarditis when the infecting agent is Strept. fecalis. Its clinical use in forms of extrapulmonary tuberculosis is in a completely experimental stage. It is not recommended in typhoid fever or in infections due to Ps. aeruginosa or P. vulgaris, and it seems to be ineffective in whooping cough. To date, neither chloromycetin nor aureomycin has shown significant signs of systemic toxicity.
 ...
PMID:The experimental and clinical use of polymyxin, chloromycetin, and aureomycin. 1811 50

Parainfectious disorders of the nervous system encompass those meningo-encephalo-radiculomyelitic conditions that are temporally associated with a systemic infection, antigenic stimuli, or toxin exposure, in the absence of evidence of direct neuronal infection or invasion of the central nervous system (CNS) or peripheral nervous system (PNS). Pathogenetic mechanisms can be due to immune-mediated processes (such as bystander activation, molecular mimicy) or the inciting insult can be due to toxic factors, as in the case of botulism. A myriad of clinical manifestations can occur including headache, seizures, and mental status changes, ranging from mood and behavioral disturbances to varying levels of alteration in consciousness. Focal neurological deficits can include aphasia, hemiparesis, or paraparesis. The PNS can also be affected leading to cranial nerve involvement, focal or multifocal neuropathies, and dysfunction of the autonomic nervous system. Diagnosis is based not only on the history, examination, laboratory, and neuroimaging data but also on epidemiological factors. The parainfectious disorders covered in this review are cat scratch disease, Lyme borreliosis, legionellosis, brucellosis, botulism, pertussis, and mycoplasma. Each is associated with a distinct organism, has both systemic and neurological manifestations, and has a different epidemiological profile.
 ...
PMID:Parainfectious meningo-encephalo-radiculo-myelitis (cat scratch disease, Lyme borreliosis, brucellosis, botulism, legionellosis, pertussis, mycoplasma). 2362 29